Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
about
Targeting the adaptive molecular landscape of castration-resistant prostate cancerRole of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerAddressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.SEOM clinical guidelines for the treatment of metastatic prostate cancerGLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate CancerEfficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German CentersPhase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancerAdvances in systemic therapies for metastatic castration-resistant prostate cancer.Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.Drug therapies for metastatic castration-resistant prostate cancer.Novel agents for castration-resistant prostate cancer: Early experience and beyond.What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?Role of taxanes in advanced prostate cancer.Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Contemporary agents in the management of metastatic castration-resistant prostate cancer.Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.The evolution of chemotherapy for the treatment of prostate cancer.Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.Current treatment strategies for advanced prostate cancer.The prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer.Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.
P2860
Q27022821-2E138D47-5027-468F-B1C2-92E7BE7B4402Q28075965-034E213F-6B94-4D35-9716-0A6CC3C9D3A1Q30244818-CE087EB3-230C-4F5C-B5FF-E68194CF710FQ34553405-6C97152B-50AE-4D20-989C-6E4A0F12CE3FQ35795342-8F5C4E8C-0428-4B9C-88D6-39BF24F28129Q35879087-913BCEF1-4872-4BED-9E30-C664818F2FB5Q36410270-BC29448D-CB82-469E-BB12-AD863171075CQ36586089-49EDABB8-CF9C-4504-9078-A116AB93D9C2Q36823062-3FBB28CC-772D-4578-88D6-E333BB2318E8Q37726362-1776E389-BDF0-4DA9-8396-DC542EB2C37FQ37735587-53E80E98-19BA-409A-B5B1-5F4E2330313DQ38232184-51BD8D77-8B05-46FC-87F8-124F6DAEDCD3Q38244522-441E0A06-9BE7-4BC5-9694-A4C420905ECFQ38276818-99AEB8E2-4A30-4AF5-A198-7318203FA83AQ38282461-65D69E37-0468-4E28-9D62-F2A2B79E0EFDQ38530028-2B49BBAC-D98A-41C2-BDE2-D3CE68EC4D7AQ38566800-CD5A8032-DC51-4EFB-978A-E6672774383DQ38574684-A70688AA-75F3-467C-B09E-28AC9A8CC2D8Q38587547-1A815911-CD50-48FA-88A4-9AC230C98F66Q38726366-69E6092D-B7E7-4910-BCE4-D36FE8AEA542Q38773368-6EC5B86D-562C-4533-9E5F-E2046A80024EQ38797560-D470C372-BFEC-4B05-80F0-56C8C3449D4AQ38865487-A6EB3D76-D1B9-435F-90D8-0449F27EF6DFQ39016544-296CCEED-2BEC-4D93-9BC0-CF45A0C58EC0Q39092924-55127764-1BF9-48F6-AEBF-1AF2D1011F54Q39205202-8F2197A0-9998-4FD0-BF89-6D987219E1F0Q41332423-4FF80176-E4D8-4EE1-8029-C39C4F8D701FQ41484469-64F5B520-C038-4DDD-851F-05521971CDF7Q44051061-FBE26A8B-3C42-482B-A5C9-A654B8172D37Q45943517-C73AFCD7-28EC-4862-B17A-D6C43B292B46Q46131083-27715DCD-355D-4EAB-8B66-FB1ACDF9E7FBQ47293703-782580D0-9E80-42B0-A53B-33B4EAABEDDEQ48037116-55B8F4E6-2B85-44B5-8312-7BC87B685503Q48107095-459469F6-0106-4C53-8DC8-BE4C0D25DFDBQ48110667-A8C8C4A0-6B7F-4FD1-844D-83B6E928764AQ48561494-B8D24E9E-7EBE-4351-8C91-2C1A5B07DAC4Q51746022-9BBAFA1B-27C0-4716-BD97-195476CA7199Q52653007-D4DB6E21-106D-4964-AD0B-B0095F86ECF2Q53737270-0E11CFE3-ABCC-4955-96D8-AFD8A3924D8CQ53822455-00DF4445-87A3-4938-97BA-F89E765468CA
P2860
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Activity of cabazitaxel in cas ...... t-generation endocrine agents.
@en
Activity of cabazitaxel in cas ...... t-generation endocrine agents.
@nl
type
label
Activity of cabazitaxel in cas ...... t-generation endocrine agents.
@en
Activity of cabazitaxel in cas ...... t-generation endocrine agents.
@nl
prefLabel
Activity of cabazitaxel in cas ...... t-generation endocrine agents.
@en
Activity of cabazitaxel in cas ...... t-generation endocrine agents.
@nl
P2093
P50
P1433
P1476
Activity of cabazitaxel in cas ...... t-generation endocrine agents.
@en
P2093
Aurelius G Omlin
Carmel J Pezaro
Christopher Parker
David Dearnaley
Diletta Bianchini
Johann S de Bono
Roberta Ferraldeschi
P304
P356
10.1016/J.EURURO.2013.11.044
P407
P577
2013-12-17T00:00:00Z